MyoKardia, Inc (acquired by BMS)
1000 Sierra Point Parkway
Brisbane, CA 94005
United States
Tel: 650-741-0900
Website: http://www.myokardia.com/
Email: info@myokardia.com
About MyoKardia, Inc (acquired by BMS)
MyoKardia’s mission is to change the world for people with serious cardiovascular disease through bold and innovative science. MyoKardia is a clinical-stage bio pharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases. The company is pioneering a precision medicine approach to its discovery and development efforts by 1) understanding the bio mechanical underpinnings of disease; 2) targeting the proteins that modulate a given condition; 3) identifying patient populations with shared disease characteristics; and 4) applying learnings from research and clinical studies to inform and guide pipeline growth and product advancement. MyoKardia’s initial focus is on small molecule therapeutics aimed at the proteins of the heart that modulate cardiac muscle contraction to address diseases driven by excessive contraction, impaired relaxation, or insufficient contraction. Among its discoveries are three clinical-stage therapeutics: mavacamten (formerly MYK-461); danicamtiv (formerly MYK-491) and MYK-224. Founded in September 2012 MyoKardia is headquartered in Brisbane, CA.
126 articles about MyoKardia, Inc (acquired by BMS)
-
MyoKardia to Present at Evercore ISI 2nd Annual HealthCONx Conference
11/27/2019
MyoKardia, Inc. (Nasdaq: MYOK), today announced that Tassos Gianakakos, Chief Executive Officer, will participate in a fireside chat at the Evercore ISI 2nd Annual HealthCONx Conference on Wednesday, December 4th, 2019, at 10:15 a.m. ET in Boston, MA.
-
Clinical Catch-Up: November 11-15
11/18/2019
It was a busy week for clinical trial announcements. Here’s a look. -
MyoKardia Announces Positive Topline Data from its Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten
11/11/2019
MyoKardia, Inc. (Nasdaq: MYOK), today announced topline data from MAVERICK-HCM, the company’s Phase 2 clinical trial of mavacamten in patients with non-obstructive hypertrophic cardiomyopathy (HCM)
-
MyoKardia Announces 48-week Data from PIONEER-OLE Study of Mavacamten
11/11/2019
MyoKardia, Inc. (Nasdaq: MYOK) today announced new data from the company’s PIONEER open-label extension (OLE) study of mavacamten for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy (HCM).
-
MyoKardia to Present at Credit Suisse 28th Annual Healthcare Conference
11/6/2019
MyoKardia, Inc. (Nasdaq: MYOK), today announced that Tassos Gianakakos, Chief Executive Officer, will participate in a fireside chat at the Credit Suisse 28th Annual Healthcare Conference on Wednesday, November 13th, 2019, at 9:45 a.m. MT (11:45 a.m. ET) in Scottsdale, AZ.
-
MyoKardia Reports Third Quarter 2019 Financial Results
11/4/2019
Completed Enrollment of 251 Patients in the Phase 3 EXPLORER-HCM Trial
-
MyoKardia Announces Abstracts Selected for Presentation at the American Heart Association Scientific Sessions 2019Company to Host Conference Call and Webcast on November 11, 2019 at 8:30 a.m. ET (5:30 a.m. PT)
11/4/2019
The abstracts include new data from the ongoing PIONEER open-label extension (PIONEER-OLE) study of mavacamten, preclinical studies of mavacamten and MYK-491, and hypertrophic cardiomyopathy (HCM) population insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe).
-
Clinical Catch-Up: October 28-Nov 1
11/4/2019
Even clinical trial announcements don’t slow down for Halloween. It was a typically busy week. Here’s a look. -
MyoKardia Announces Positive MYK-491 Data; Advancing Program into Targeted Genetic Dilated Cardiomyopathy Population
10/28/2019
Interim Data Demonstrated Favorable Safety and Activity Profile in Phase 2a Multiple-Ascending Dose Study
-
MyoKardia to Present at 2019 Cantor Global Healthcare Conference
9/26/2019
MyoKardia, Inc., announced that Taylor Harris, Chief Financial Officer, will participate in a fireside chat at the 2019 Cantor Global Healthcare Conference on Thursday, October 3, 2019, at 4:10 p.m. ET in New York, NY.
-
MyoKardia to Evaluate Mavacamten as an Alternative to Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Patients
9/10/2019
Planned Study Will Assess Effect of Mavacamten on the Need for SRT Among HCM Patients Referred for Invasive Procedures
-
MyoKardia to Participate in September 2019 Investor Conferences
8/28/2019
MyoKardia, Inc., announced its participation in the following upcoming investor conferences:
-
MyoKardia Announces Abstracts Selected for Presentation at the European Society of Cardiology Congress 2019
8/26/2019
MyoKardia, Inc. announced the presentation of three abstracts at the upcoming European Society of Cardiology Congress taking place August 31 – September 4, 2019 in Paris, France.
-
Clinical Catch-up for August 19-23
8/26/2019
Biopharma companies large and small are involved in numerous clinical trials. Here’s a look at some of the top stories from last week. -
MyoKardia Begins Dosing in Phase 1 Clinical Study of MYK-224 for Hypertrophic Cardiomyopathy
8/21/2019
MyoKardia, Inc. announced that it has dosed the first subjects in a Phase 1 clinical study of MYK-224, a small molecule candidate being developed for the treatment of hypertrophic cardiomyopathy.
-
MyoKardia Launches 2nd Annual MyoSeeds™ Research Grants Program to Advance Independent Research in Heart Disease
8/15/2019
Pre-Application Letters of Intent are Due September 13 for the 2019-2020 Funding Cycle
-
MyoKardia Reports Second Quarter 2019 Financial Results
8/7/2019
MyoKardia, Inc. reported financial results for the second quarter ended June 30, 2019.
-
MyoKardia to Report Second Quarter 2019 Financial Results on Wednesday, August 7, 2019
7/31/2019
MyoKardia, Inc., announced that it will report second quarter 2019 financial and operating results on Wednesday, August 7, 2019.
-
MyoKardia Announces HCM Program Updates: Accelerates Timing for Mavacamten Topline Phase 3 Data; Re-acquires U.S. Royalty Rights to HCM Programs from Sanofi
7/18/2019
MyoKardia, Inc. announced updates related to its hypertrophic cardiomyopathy treatment portfolio, including lead therapeutic candidate, mavacamten.
-
MyoKardia Publishes Data in Nature Digital Medicine Showing Potential of Wrist-Worn Biosensor to Screen for Hypertrophic Cardiomyopathy
6/24/2019
Continuous Monitoring with Wearable Device Detected Distinct Pulse Wave Patterns in Obstructive Hypertrophic Cardiomyopathy Patients as Compared to Healthy Volunteers